Warfarin (Coumadin)
Also known as Apo-Warfarin, Jantoven, Mylan-Warfarin, Novo-Warfarin, or Taro-Warfarin.
General information
Class/mechanism: Vitamin K antagonist, inhibits the production of several vitamin K-dependent clotting factors, such as factor II (prothrombin), factor VII (proconvertin), factor IX (plasma thromboplastin component), factor X (Stuart factor), protein C, and protein S. Warfarin interferes with regeneration of vitamin K1 epoxide by inhibiting the C1 subunit of vitamin K epoxide reductase (VKORC1). Some nucleotide polymorphisms in VKOR and CYP2C9 variants have been associated with different warfarin dose requirements.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information[1].
Patient drug information
- Warfarin (Coumadin) package insert PDF pages 8-10[1]
- Warfarin (Coumadin) patient drug information (UpToDate)[3]